openPR Logo
Press release

Angiotensin Receptor Blockers & Neprilysin Inhibitors Market to Witness Exponential Growth by 2025

04-10-2018 05:52 PM CET | Health & Medicine

Press release from: Transparency Market Research

Angiotensin Receptor Blockers & Neprilysin Inhibitors Market

Angiotensin receptor blockers and neprilysin inhibitors is a combination of two drugs viz. a neprilysin inhibitor and an angiotensin receptor blocker. The inhibition of neprilysin helps in increasing the level of natriuretic peptides. Angiotensin receptor blockers & neprilysin inhibitors factor is very important for the maintenance of balance of sodium and fluids in the body through vasodilation, diuresis, and natriuresis. Angiotensin receptor blockers & neprilysin inhibitors helps in reducing the risk of heart failure and decreasing the blood pressure. The inhibition of activating angiotensin-II receptor causes decline in the production of aldosterone, vasodilation, and decrease in the production of vasopressin. This, in turn, results in decreased blood pressure. Risky complications of the heart failure are reduced with the use of a combination of neprilysin inhibitors and angiotensin receptor blockers.

The function of the heart is to pump the blood to the entire body and help in transferring nutrients and oxygen to every cell of the body. The failure of the heart to perform this key function adequately is simply known as congestive heart failure. The term ‘congestive heart failure’ can be used only if the heart receives a sufficient volume of the blood from the incoming blood vessels at a normal filling pressure, but is not able to pump enough blood to the body. On the other hand, if the heart itself does not receive a sufficient volume of the blood in the first place from the incoming blood vessels, the condition is not known as congestive heart failure. Congestive heart failure is the indication that occurs if the fluid backs up behind the failing ventricle, or if there is a decrease in the flow of blood from the heart (i.e. the cardiac output), or both.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41276

Global Angiotensin Receptor Blockers & Neprilysin Inhibitors Market: Drivers and Restraints

The increasing prevalence of the congestive heart failure all over the globe is driving the Angiotensin Receptor Blockers & Neprilysin Inhibitors Market. According to Centers for Disease Control & Prevention (CDC), in the U.S., approximately 5.7 million adults are living with heart failure. Within around five years of the diagnosis of the heart failure, about 50% of them die. The cost incurred to the nation due to heart failures is approximately US$ 30.7 Bn every year. This includes medications to treat the heart failure, missed days of work, and health care services. Certain diseases that hamper the functioning of the heart are diabetes, heart attack, high blood pressure, coronary heart disease (the most common type of heart disease). The risk of the heart failure increases due to obesity; lack of enough physical activity; consumption of foods high in sodium, cholesterol, and fats; and smoking of tobacco.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=41276

Global Angiotensin Receptor Blockers & Neprilysin Inhibitors Market: Key Segments

The global angiotensin receptor blockers & neprilysin inhibitors market can be segmented based on distribution channel and region. Based on distribution channel, the Angiotensin Receptor Blockers & Neprilysin Inhibitors market can be classified into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment is anticipated to dominate the Angiotensin Receptor Blockers & Neprilysin Inhibitors market during the forecast period, owing to increased availability of angiotensin receptor blockers and neprilysin inhibitors in hospital pharmacies.

Geographically, the global angiotensin receptor blockers & neprilysin inhibitors market can be categorized into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest Angiotensin Receptor Blockers & Neprilysin Inhibitors market share in 2016, due to increased research and development of angiotensin receptor blockers and neprilysin inhibitors in the region. Europe held the second-largest Angiotensin Receptor Blockers & Neprilysin Inhibitors market share in 2016, due to increasing prevalence of heart failures in the region. The Angiotensin Receptor Blockers & Neprilysin Inhibitors market in Asia Pacific is anticipated to expand at a moderate pace from 2017 to 2025, owing to increasing initiatives regarding health care by governments in the region. The Angiotensin Receptor Blockers & Neprilysin Inhibitors markets in Middle East & Africa and Latin America are anticipated to expand at a moderate pace during the forecast period, due to growing awareness regarding angiotensin receptor blockers and neprilysin inhibitors in these regions.

Global Angiotensin Receptor Blockers & Neprilysin Inhibitors Market: Key Players

Only one company i.e. Novartis AG is a key player operating in the global angiotensin receptor blockers & neprilysin inhibitors market.

View Report -

https://www.transparencymarketresearch.com/angiotensin-receptor-blockers-neprilysin-inhibitors-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angiotensin Receptor Blockers & Neprilysin Inhibitors Market to Witness Exponential Growth by 2025 here

News-ID: 1010446 • Views: 313

More Releases from Transparency Market Research

Meningitis Diagnostic Testing Market Outlook, Trend, Growth and Share Estimation …
Meningitis Diagnostic Testing Market: Overview The global meningitis diagnostic testing market was valued over US$ 105.5 Mn in 2016 and is projected to register cumulative annual growth rate (CAGR) of over 3.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled "Meningitis Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025". The report suggests that rising demand for innovative
Metformin Hydrochloride API Market to Expand at a CAGR of ~5% from 2021 to 2031
Metformin Hydrochloride API Market: Introduction According to the report, the global metformin hydrochloride API market was valued at ~US$ 300 Mn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031. Metformin hydrochloride is primarily used in the treatment of diabetes. The prevalence of diabetes is expected to increase across the world due to change in lifestyle and factors such as malnutrition and genetic mutations.
Telehealth Market to Reach the Value of US$ 15 Bn by the End of 2028
Telehealth Market: Introduction According to the report, the global telehealth market was valued at US$ 7.8 Bn in 2020 and is projected to expand at a CAGR of 7% from 2021 to 2028. The global telehealth market has witnessed strong growth in the past few years. Telehealth is no longer an option, but a necessity due to the increasing dangers of COVID-19. Read Report Overview - https://www.transparencymarketresearch.com/telehealth-market.html The crisis presents an opportunity
Lyme Disease Treatment Market Growth Trends, Current Demand, and Development Rep …
Lyme Disease Treatment Market: Introduction According to the report, the global Lyme disease treatment market was valued at US$ 1.58 Bn in 2020 and is projected to expand at a CAGR of ~6% from 2021 to 2031. Increase in pet ownership, surge in awareness & adoption of veterinary care, and rise in healthcare expenditure on animals are anticipated to drive the global Lyme disease treatment market from 2021 to 2031.North America

All 5 Releases


More Releases for Angiotensin

Angiotensin Modulators Market 2020 Clinical Survey Report to 2026
Angiotensin Modulators -Pipeline Insight, 2020 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Angiotensin Modulators Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has
Type 2 Angiotensin II Receptor Global Market Research Report 2025
Type 2 Angiotensin II Receptor Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/type-2-angiotensin-ii-receptor-market/80995 The report firstly introduced the Type 2 Angiotensin II
Angiotensin Converting Enzyme Inhibitors Market to Develop Rapidly by 2025
Angiotensin converting enzyme inhibitors are a group of drugs used for the treatment of heart failure, high blood pressure (hypertension), or decrease complications of myocardial infarction (heart attack). These drugs are also useful in slowing down kidney disease progression in patients with chronic kidney disease or kidney disease in diabetic patients. The mechanism of action of angiotensin converting enzyme inhibitors is to decrease the amount of angiotensin II produced. Angiotensin
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
Global Angiotensin II Receptor Market Sales, Revenue Status, Application & Forec …
The market for "Angiotensin II Receptor" is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Angiotensin II Receptor Market Research Report 2018” which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore,
Global Type 2 Angiotensin II Receptor Market Pipeline Review, H2 2017
"The Report Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest